Analyst Price Target is $14.67
▲ +27.65% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ironwood Pharmaceuticals in the last 3 months. The average price target is $14.67, with a high forecast of $16.00 and a low forecast of $13.00. The average price target represents a 27.65% upside from the last price of $11.49.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Ironwood Pharmaceuticals. This rating has held steady since August 2022, when it changed from a Hold consensus rating.
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
Read More